Shares of Viatris Inc. VTRS advanced 1.72% to $11.25 Friday, on what proved to be an all-around rough trading session for the ...

Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, 2025.

Shares of Viatris Inc. VTRS advanced 1.19% to $11.06 Thursday, on what proved to be an all-around dismal trading session for ...

and Viatris is profitable, guiding for Adjusted EBITDA of $4.7bn, free cash flow of $2.37bn, and adjusted earnings per share ("EPS") of $2.64, in 2024, which translates to a price to earnings ("P ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

As Leo stands in his office, overseeing the entrance of Viatris' bustling office in the Netherlands, he reflects on the 50 years that have shaped his journey with the company. From his early days ...

Overall, it was a very strong quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates and a solid beat of analysts’ EPS estimates. “I am very pleased to ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. The generic ...

Earnings per share (EPS) reached $4.68, surpassing the forecast of $2.11. Revenue came in at $2.3 billion, beating the expectation of $1.841 billion. Net income soared to $1.3 billion from $273.4 ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

This print exceeded analysts’ expectations by 1.5%. Overall, it was a very strong quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates and a solid beat of ...